 |
0 Diseases |  |
24 Trials |
|
24 Trials |  |
921 News |  |
| «12...891011121314151617181920» |
- ||||| Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: PIONEER 4: Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Sep 5, 2017
P3, N=690, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting
- || Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes. (clinicaltrials.gov) - Aug 31, 2017
P1, N=52, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2017 --> Dec 2017
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects (clinicaltrials.gov) - Aug 18, 2017
P1, N=41, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Aug 2017 --> Dec 2017 Active, not recruiting --> Completed
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: PIONEER 8: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (clinicaltrials.gov) - Jul 25, 2017
P3, N=720, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects. (clinicaltrials.gov) - Jun 27, 2017
P1, N=45, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed, Monotherapy: PIONEER 9: Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jun 22, 2017
P3, N=240, Active, not recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed, Combination therapy: PIONEER 10: Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jun 21, 2017
P3, N=455, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jun 14, 2017
P1, N=22, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: Oct 2017 --> Feb 2018
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Clinical: PIONEER 1: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (clinicaltrials.gov) - May 24, 2017
P3, N=704, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Oct 2017 --> Feb 2018 Recruiting --> Active, not recruiting
- |||||||||| Ozempic (semaglutide SC once-weekly) / Novo Nordisk
Clinical: SUSTAIN 8: Efficacy and Safety of Semaglutide Versus Canagliflozin as add-on to Metformin in Subjects With Type 2 Diabetes (clinicaltrials.gov) - May 8, 2017
P3, N=784, Recruiting, Sponsor: Novo Nordisk A/S
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects (clinicaltrials.gov) - Apr 28, 2017
P1, N=41, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: PIONEER 7: Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. (clinicaltrials.gov) - Mar 29, 2017
P3, N=500, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: Mar 2019 --> Feb 2018
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Clinical: PIONEER 2: Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Mar 10, 2017
P3, N=816, Active, not recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Mar 2019 --> Feb 2018 Recruiting --> Active, not recruiting
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: PIONEER 7: Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. (clinicaltrials.gov) - Feb 27, 2017
P3, N=500, Active, not recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: PIONEER 4: Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Feb 13, 2017
P3, N=690, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2018 --> Aug 2017
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: PIONEER 8: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (clinicaltrials.gov) - Feb 11, 2017
P3, N=720, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Apr 2018 --> Aug 2017 Not yet recruiting --> Recruiting
- |||||| Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Phase classification, Monotherapy: PIONEER 9: Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Feb 9, 2017
P3, N=240, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Phase classification: P2/3 --> P3
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: PIONEER 3: Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Feb 9, 2017
P3, N=1860, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting | Phase classification: P2/3 --> P3 Trial primary completion date: Mar 2018 --> Feb 2017
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open, Combination therapy: PIONEER 10: Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Feb 7, 2017
P3, N=455, Recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Mar 2018 --> Feb 2017 Not yet recruiting --> Recruiting
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Clinical: PIONEER 2: Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Feb 6, 2017
P3, N=816, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2018 --> Aug 2017
- | Rybelsus (semaglutide oral) / Novo Nordisk
Trial completion: A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females (clinicaltrials.gov) - Feb 6, 2017
P1, N=25, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Mar 2018 --> Aug 2017 Active, not recruiting --> Completed
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects (clinicaltrials.gov) - Feb 3, 2017
P1, N=41, Recruiting, Sponsor: Novo Nordisk A/S
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: PIONEER 6: A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jan 23, 2017
P3, N=3176, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial, Monotherapy: PIONEER 9: Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jan 19, 2017
P3, N=240, Recruiting, Sponsor: Novo Nordisk A/S
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial: PIONEER 8: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Insulin (clinicaltrials.gov) - Jan 13, 2017
P3, N=720, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
New P2/3 trial, Monotherapy: PIONEER 9: Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jan 11, 2017
P2/3, N=240, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial, Combination therapy: PIONEER 10: Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jan 8, 2017
P3, N=455, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: A Trial Investigating the Effect of Oral Semaglutide on the Pharmacokinetics of Furosemide and Rosuvastatin in Healthy Subjects (clinicaltrials.gov) - Jan 5, 2017
P1, N=41, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects. (clinicaltrials.gov) - Dec 30, 2016
P1, N=45, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes. (clinicaltrials.gov) - Dec 27, 2016
P1, N=52, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial primary completion date: PIONEER 7: Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. (clinicaltrials.gov) - Dec 5, 2016
P3, N=500, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2018 --> Mar 2019
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial initiation date: PIONEER 6: A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Oct 31, 2016
P3, N=3176, Not yet recruiting, Sponsor: Novo Nordisk A/S
Trial primary completion date: Mar 2018 --> Mar 2019 Initiation date: Oct 2016 --> Jan 2017
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects. (clinicaltrials.gov) - Oct 29, 2016
P1, N=45, Recruiting, Sponsor: Novo Nordisk A/S
Initiation date: Oct 2016 --> Jan 2017 Not yet recruiting --> Recruiting
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
Clinical: PIONEER 1: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (clinicaltrials.gov) - Oct 19, 2016
P3, N=704, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Levothyroxine and the Influence of Co-administered Tablets on the Pharmacokinetics of Semaglutide Administered Orally in Healthy Subjects. (clinicaltrials.gov) - Sep 29, 2016
P1, N=45, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: PIONEER 7: Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. (clinicaltrials.gov) - Sep 22, 2016
P3, N=500, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: PIONEER 5: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment (clinicaltrials.gov) - Sep 22, 2016
P3, N=324, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial: PIONEER 1: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes Mellitus Treated With Diet and Exercise Only (clinicaltrials.gov) - Sep 20, 2016
P3, N=704, Not yet recruiting, Sponsor: Novo Nordisk A/S
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: PIONEER 3: Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Sep 14, 2016
P3, N=1860, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||||| Rybelsus (semaglutide oral) / Novo Nordisk
Clinical: PIONEER 2: Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Sep 9, 2016
P3, N=816, Recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||| Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: PIONEER 4: Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Sep 9, 2016
P3, N=690, Recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment closed: A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females (clinicaltrials.gov) - Aug 31, 2016
P1, N=25, Active, not recruiting, Sponsor: Novo Nordisk A/S
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes. (clinicaltrials.gov) - Aug 23, 2016
P1, N=52, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk
Clinical: PIONEER 2: Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Aug 11, 2016
P3, N=816, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||||||| Victoza (liraglutide) / Novo Nordisk, Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial: PIONEER 4: Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Aug 11, 2016
P3, N=690, Not yet recruiting, Sponsor: Novo Nordisk A/S
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial: PIONEER 7: Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus. (clinicaltrials.gov) - Jul 29, 2016
P3, N=500, Not yet recruiting, Sponsor: Novo Nordisk A/S
- | Rybelsus (semaglutide oral) / Novo Nordisk
New P1 trial: A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females (clinicaltrials.gov) - Jul 27, 2016
P1, N=25, Recruiting, Sponsor: Novo Nordisk A/S
- ||||| Rybelsus (semaglutide oral) / Novo Nordisk
Trial initiation date: PIONEER 6: A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jul 19, 2016
P3, N=3176, Not yet recruiting, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Initiation date: Jul 2016 --> Oct 2016
- |||||||||| Rybelsus (semaglutide oral) / Novo Nordisk
New P3 trial: PIONEER 5: Efficacy and Safety of Oral Semaglutide Versus Placebo in Subjects With Type 2 Diabetes and Moderate Renal Impairment (clinicaltrials.gov) - Jul 11, 2016
P3, N=324, Not yet recruiting, Sponsor: Novo Nordisk A/S
- Rybelsus (semaglutide oral) / Novo Nordisk
Enrollment open: A Trial Investigating the Effect of Oral Semaglutide Compared With Placebo on Postprandial Glucose and Triglyceride Metabolism, Energy Intake, Appetite Sensations and Gastric Emptying in Subjects With Type 2 Diabetes (clinicaltrials.gov) - Jun 28, 2016
P1, N=22, Recruiting, Sponsor: Novo Nordisk A/S
Initiation date: Jul 2016 --> Oct 2016 Not yet recruiting --> Recruiting